MCID: LNG099
MIFTS: 62

Lung Disease

Categories: Blood diseases, Respiratory diseases

Aliases & Classifications for Lung Disease

MalaCards integrated aliases for Lung Disease:

Name: Lung Disease 12 15 17
Lung Diseases 54 42 44 15 71
Abnormality of the Lung 6

Classifications:



External Ids:

Disease Ontology 12 DOID:850
MeSH 44 D008171
NCIt 50 C3198
SNOMED-CT 67 266374002
ICD10 32 J60-J70 J98.4
UMLS 71 C0024115

Summaries for Lung Disease

MedlinePlus : 42 When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary : Lung Disease, also known as lung diseases, is related to interstitial lung disease and pulmonary disease, chronic obstructive, and has symptoms including dyspnea, hemoptysis and apnea. An important gene associated with Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are Metabolism of proteins and Toll-like Receptor Signaling Pathway. The drugs Cefuroxime and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include lung, endothelial and neutrophil, and related phenotypes are homeostasis/metabolism and mortality/aging

Disease Ontology : 12 A lower respiratory tract disease in which the function of the lungs is adversely affected by narrowing or blockage of the airways resulting in poor air flow, a loss of elasticity in the lungs that produces a decrease in the total volume of air that the lungs are able to hold, and clotting, scarring, or inflammation of the blood vessels that affect the ability of the lungs to take up oxygen and to release carbon dioxide.

Related Diseases for Lung Disease

Diseases related to Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1403)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 33.8 TNF TERT SFTPD SFTPC SFTPB SFTPA2
2 pulmonary disease, chronic obstructive 33.3 TNF SFTPD SFTPB SERPINA1 IL1B IL10
3 pulmonary fibrosis, idiopathic 33.1 TNF TERT SFTPD SFTPC SFTPB SFTPA2
4 pulmonary fibrosis 33.1 TERT SFTPD SFTPC SFTPA2 SFTPA1 MUC5B
5 interstitial pneumonitis, desquamative, familial 33.1 SFTPD SFTPC SFTPB SFTPA2 MUC5B ABCA3
6 nontuberculous mycobacterial lung disease 33.0 TNF CFTR
7 alpha-1-antitrypsin deficiency 33.0 TNF SERPINA1 ELANE CXCL8 CFTR
8 cystic fibrosis 33.0 TNF SFTPD SFTPC SERPINA1 MUC5B IL1B
9 surfactant metabolism dysfunction, pulmonary, 1 32.9 SFTPC SFTPB ABCA3
10 rheumatoid arthritis interstitial lung disease 32.9 TNF SFTPD
11 anthracosis 32.9 TNF IL1B CXCL8
12 pulmonary hypertension 32.9 TNF SFTPC SFTPB SERPINA1 IL1B IL10
13 respiratory failure 32.8 TNF SFTPD SFTPC SFTPB SERPINA1 IL1B
14 idiopathic interstitial pneumonia 32.7 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 MUC5B
15 bronchopulmonary dysplasia 32.7 SFTPB ELANE CXCL8
16 antisynthetase syndrome 32.7 MUC5B IL1B IFIH1
17 pneumonia 32.7 TNF SFTPD SFTPC SFTPB SERPINA1 MUC5B
18 bronchiolitis 32.7 TNF SFTPD IL1B IL10 CXCL8
19 extrinsic allergic alveolitis 32.7 SFTPD IL1B IL10 ELANE CXCL8
20 pneumoconiosis 32.7 TNF SERPINA1 MUC5B IL1B IL10 CXCL8
21 surfactant dysfunction 32.6 SFTPC SFTPB SFTPA1 ABCA3
22 pulmonary alveolar microlithiasis 32.6 SFTPD SFTPA2 ABCA3
23 asthma 32.5 TNF SFTPD SERPINA1 IL1B IL10 ELANE
24 bronchiolitis obliterans 32.5 TNF SFTPD IL10 CXCL8
25 cryptogenic organizing pneumonia 32.5 TNF SFTPD SFTPC SFTPA2 CXCL8
26 aspergillosis 32.5 TNF SFTPD SFTPA2 SFTPA1 IL1B IL10
27 silicosis 32.5 TNF SFTPD IL1B IL10 CXCL8
28 pulmonary alveolar proteinosis 32.5 TNF SFTPD SFTPC SFTPB SFTPA1 IL10
29 acute interstitial pneumonia 32.4 TNF TERT SFTPD SFTPC SFTPB SFTPA2
30 bronchiectasis 32.4 TNF SERPINA1 IL1B ELANE CXCL8 CFTR
31 respiratory distress syndrome in premature infants 32.4 SFTPC SFTPB SFTPA1 ABCA3
32 common variable immunodeficiency 32.3 TNF SERPINA1 IL1B IL10
33 sleep disorder 32.3 TNF IL1B IL10 CXCL8
34 meconium aspiration syndrome 32.3 TNF SFTPB CXCL8 ABCA3
35 pulmonary immaturity 32.2 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 ABCA3
36 bronchitis 32.2 TNF SERPINA1 IL1B IL10 ELANE CXCL8
37 bagassosis 32.2 TNF IL1B CXCL8
38 connective tissue disease 32.2 TNF SFTPD IL1B IL10 CXCL8
39 nonspecific interstitial pneumonia 32.2 SFTPD SFTPC MUC5B IFIH1 ABCA3
40 klebsiella pneumonia 32.2 TNF IL1B IL10 CXCL8
41 pulmonary hemosiderosis 32.1 SFTPB ABCA3
42 myositis 32.0 TNF IL1B IFIH1 CXCL8
43 adult respiratory distress syndrome 32.0 TNF SFTPD SFTPC SFTPB IL1B IL10
44 autoimmune disease 31.8 TNF IL1B IL10 IFIH1 CXCL8
45 mycobacterium abscessus 31.8 TNF SERPINA1 CXCL8 CFTR
46 gastroesophageal reflux 31.7 TNF TERT IL1B ELANE CXCL8
47 exanthem 31.6 TNF IL1B IL10 IFIH1 CXCL8
48 pulmonary edema 31.6 TNF IL1B IL10 CXCL8 CFTR
49 enterocolitis 31.6 TNF IL10 CXCL8
50 sleep apnea 31.6 TNF IL1B IL10 CXCL8

Graphical network of the top 20 diseases related to Lung Disease:



Diseases related to Lung Disease

Symptoms & Phenotypes for Lung Disease

UMLS symptoms related to Lung Disease:


dyspnea, hemoptysis, apnea, snoring, coughing, labored breathing

MGI Mouse Phenotypes related to Lung Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ABCA3 CFTR DYNC2H1 ELANE IFIH1 IL10
2 mortality/aging MP:0010768 10.06 ABCA3 CFTR DYNC2H1 ELANE IFIH1 IL10
3 immune system MP:0005387 10.03 CFTR ELANE IFIH1 IL10 IL1B ITGA3
4 neoplasm MP:0002006 9.5 ELANE IL10 IL1B ITGA3 SFTPC TERT
5 respiratory system MP:0005388 9.4 ABCA3 CFTR DYNC2H1 IL10 ITGA3 MUC5B

Drugs & Therapeutics for Lung Disease

Drugs for Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 600)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Beractant Approved Phase 4 108778-82-1
5
Iron Approved Phase 4 7439-89-6 23925 29936
6
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
7
Simvastatin Approved Phase 4 79902-63-9 54454
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
10
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
11
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
12
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
13
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
14
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
15
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
16
Polyestradiol phosphate Approved Phase 4 28014-46-2
17
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
18 Orange Approved Phase 4
19
Morphine Approved, Investigational Phase 4 57-27-2 5288826
20
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
21
Mycophenolic acid Approved Phase 4 24280-93-1 446541
22
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
23
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
24
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
25
Ledipasvir Approved Phase 4 1256388-51-8 67505836
26
Palivizumab Approved, Investigational Phase 4 188039-54-5
27
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
28
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
29
Phenylephrine Approved Phase 4 59-42-7 6041
30
Olodaterol Approved Phase 4 868049-49-4
31
Theophylline Approved Phase 4 58-55-9 2153
32
Bisoprolol Approved Phase 4 66722-44-9 2405
33
Fosinopril Approved Phase 4 98048-97-6 55891
34
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
35
Lactitol Approved, Investigational Phase 4 585-86-4 157355
36
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
37
Norflurane Approved, Experimental Phase 4 811-97-2
38
Desflurane Approved Phase 4 57041-67-5 42113
39
Sultamicillin Approved, Investigational Phase 4 76497-13-7
40
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
41
Celiprolol Approved, Investigational Phase 4 56980-93-9
42
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
43
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
44
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
45
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
46
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
47
Remifentanil Approved Phase 4 132875-61-7 60815
48
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
49
Nintedanib Approved Phase 4 656247-17-5 56843413
50
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 3614)
# Name Status NCT ID Phase Drugs
1 Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Study of Intermittent, Prophylactic Antibiotic Treatment With Azithromycin Unknown status NCT00132860 Phase 4 azithromycin
2 Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study. Unknown status NCT00637065 Phase 4 Bosentan;Placebo
3 Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
4 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
5 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
6 Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
7 Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent) Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
8 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
9 Pulmonary Effects of the Combination of Metoprolol and Formoterol in COPD Unknown status NCT00288548 Phase 4 Metoprolol
10 Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO) Unknown status NCT03563001 Phase 4 Budesonide(160ug) and Formoterol(4.5ug) bid
11 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
12 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
13 Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients Unknown status NCT02547558 Phase 4 Indacaterol
14 A Multi-Center, Prospective, Clinical Trial Designed to Study the Efficacy of One-Way Valve Implantation Based on a New Treatment Algorithm in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
15 Impact of Exercise on Lung Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT03551197 Phase 4 Budesonide and formoterol bid
16 Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
17 Effects of GLP-1 Receptor Agonist Treatment on Pulmonary Function and Quality of Life in Obese Patients With Chronic Obstructive Pulmonary Disease. Unknown status NCT03466021 Phase 4 Liraglutide;Placebo
18 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Unknown status NCT01116063 Phase 4 Inhaled iloprost
19 The Lung Attack Alert Study Unknown status NCT01107613 Phase 4
20 Advair - CRP Study Unknown status NCT00120978 Phase 4 Advair;Flovent
21 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
22 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
23 Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD. Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
24 Long-term Effect of an Health Education Program on Daily Physical Activity in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease Unknown status NCT02924870 Phase 4
25 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
26 Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Ipratropium/Albuterolin Chinese Patients With Moderate-to-severe COPD. Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
27 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
28 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype Unknown status NCT01431625 Phase 4
29 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
30 Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System Unknown status NCT01460108 Phase 4
31 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
32 Evaluation and Treatment of Small Airways in COPD Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
33 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? Unknown status NCT02171338 Phase 4
34 Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
35 The Effects of Simvastatin in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
36 Exacerbation's Prevention in Patients With COPD in GOLD IV Stage (Very Severe) With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
37 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
38 Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation Unknown status NCT01513655 Phase 4
39 An Efficacy Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
40 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD:a Multicentre Randomised Controlled Trial Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
41 Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program Unknown status NCT03364829 Phase 4 Indacaterol/Glycopyrronium
42 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD:a Randomised Controlled Trial Unknown status NCT02197871 Phase 4
43 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
44 MAESTRAL - A Prospective, Multinational, Multicenter, Randomized, Double Blind, Double Dummy, Controlled Study Comparing the Efficacy and Safety of Moxifloxacin to That of Amoxicillin Clavulanic Acid for the Treatment of Subjects With Acute Exacerbations of Chronic Bronchitis. Completed NCT00656747 Phase 4 Avelox (Moxifloxacin, BAY12-8039);Amoxicillin clavulanic acid
45 Effects of Dexmedetomidine on Oxygenation and Lung Mechanics in Morbidly Obese Patients Undergoing Bariatric Operations: A Randomized Controlled Trial Completed NCT02843698 Phase 4 Dexmedetomidine;Normal saline
46 Effects of Pulmonary Rehabilitation in Interstitial Lung Diseases: a Prospective Randomized Controlled Trial Completed NCT00882817 Phase 4
47 Digital Auscultation Tool - Development of an Innovative Approach - Using Modern Technologies - to Improve the Diagnosis of Rare Lung Diseases - Expanded Data Collection Idiopathic Pulmonary Fibrosis Completed NCT03503188 Phase 4
48 Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease Completed NCT02622022 Phase 4 Morphine hydrochloride
49 ANTEAB: a Study of Early Antibiotherapy in the ICU Management of Acute Exacerbations of COPD Completed NCT00190437 Phase 4 Amoxicillin-clavulanic
50 GR Activity in Induced Sputum Macrophages, and a Change in Inflammatory Biomarkers 2-hours After a Single Dose of Either Symbicort®/Budesonide/Formoterol or in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01787097 Phase 4 Symbicort® total dose 400ug/12ug;Symbicort® total dose 800ug/24ug;Formoterol 24ug;BUD total dose 800ug

Search NIH Clinical Center for Lung Disease

Cochrane evidence based reviews: lung diseases

Genetic Tests for Lung Disease

Anatomical Context for Lung Disease

MalaCards organs/tissues related to Lung Disease:

40
Lung, Endothelial, Neutrophil, T Cells, Bone Marrow, Skeletal Muscle, Skin

Publications for Lung Disease

Articles related to Lung Disease:

(show top 50) (show all 43555)
# Title Authors PMID Year
1
Veno-Venous Extracorporeal Membrane Oxygenation in COVID-19-Where Are We Now? 42
33525739 2021
2
Prone positioning as an emerging tool in the care provided to patients infected with COVID-19: a scoping review. 42
33439949 2021
3
Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. 42
33494244 2021
4
Decreased Cyp2E1 mRNA expression in human leucocytes in patients with fibrotic and inflammatory lung diseases. 54 61
20514434 2010
5
Surfactant protein (SP)-A and SP-D as antimicrobial and immunotherapeutic agents. 54 61
20230362 2010
6
Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. 61 54
20511978 2010
7
Characteristics of disorders associated with genetic mutations of surfactant protein C. 54 61
20403820 2010
8
Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition. 54 61
20082309 2010
9
Nrf2 protects against airway disorders. 54 61
19646463 2010
10
The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. 54 61
20423679 2010
11
Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation. 61 54
20448817 2010
12
Airway proteins involved in bacterial clearance susceptible to cathepsin G proteolysis. 61 54
19679607 2010
13
4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. 54 61
19904934 2010
14
Development of carbohydrate-derived inhibitors of acid sphingomyelinase. 61 54
20005726 2010
15
Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. 61 54
19762563 2010
16
Lack of association of immune-response-gene polymorphisms with susceptibility to sarcoidosis in Slovenian patients. 61 54
20082271 2010
17
TNFalpha-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism. 61 54
19850966 2009
18
Surfactant protein C in canine pulmonary fibrosis. 54 61
19747194 2009
19
Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. 54 61
19759179 2009
20
Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. 61 54
19797509 2009
21
Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis. 61 54
19443536 2009
22
Methemoglobin to cumulative nitric oxide ratio and response to inhaled nitric oxide in PPHN. 54 61
19554014 2009
23
Histone deacetylase-2 and airway disease. 61 54
19812111 2009
24
Long-acting local anesthetics attenuate FMLP-induced acute lung injury in rats. 54 61
19690261 2009
25
Natriuretic peptides for the prediction of severely impaired peak VO2 in patients with lung disease. 61 54
19375295 2009
26
New surfactant protein C gene mutations associated with diffuse lung disease. 61 54
19443464 2009
27
Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. 61 54
19372250 2009
28
Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. 54 61
19596921 2009
29
Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors. 61 54
19349911 2009
30
IL1B polymorphisms modulate cystic fibrosis lung disease. 61 54
19431193 2009
31
Defective organellar acidification as a cause of cystic fibrosis lung disease: reexamination of a recurring hypothesis. 54 61
19329540 2009
32
Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3. 61 54
19292764 2009
33
Generation of bleomycin-induced lung fibrosis is independent of IL-16. 54 61
19232499 2009
34
Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. 54 61
19242412 2009
35
Association of MBL2, TGF-beta1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis. 54 61
19466271 2009
36
Unimpaired lysosomal acidification in respiratory epithelial cells in cystic fibrosis. 61 54
19136560 2009
37
Exhaled nitric oxide levels in alpha-1-antitrypsin PiMZ subjects. 54 61
19019191 2009
38
Genetic association of SP-C with duration of preterm premature rupture of fetal membranes and expression in gestational tissues. 54 61
19735006 2009
39
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. 61 54
19707408 2009
40
Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer. 54 61
18855882 2008
41
Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. 61 54
19017998 2008
42
Clinical importance of bronchoalveolar lavage fluid and blood cytokines, surfactant protein D, and Kerbs von Lungren 6 antigen in idiopathic pulmonary alveolar proteinosis. 54 61
19046553 2008
43
Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. 61 54
19009622 2008
44
Gastrin-releasing peptide, immune responses, and lung disease. 54 61
19076373 2008
45
Update on gene modifiers in cystic fibrosis. 61 54
18812833 2008
46
Potential role of high-mobility group box 1 in cystic fibrosis airway disease. 61 54
18658107 2008
47
Tumor necrosis factor-alpha in airway secretions from cystic fibrosis patients upregulate endothelial adhesion molecules and induce airway epithelial cell apoptosis: implications for cystic fibrosis lung disease. 54 61
19144271 2008
48
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 54 61
18784990 2008
49
[Clinical value of combined detection of serum tumor markers in lung cancer diagnosis]. 54 61
19024326 2008
50
DNA vector augments inflammation in epithelial cells via EGFR-dependent regulation of TLR4 and TLR2. 54 61
18403779 2008

Variations for Lung Disease

ClinVar genetic disease variations for Lung Disease:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 DYNC2H1 NM_001377.3(DYNC2H1):c.5920G>T (p.Gly1974Ter) SNV Likely pathogenic 978635 11:103048330-103048330 11:103177601-103177601
2 DYNC2H1 NM_001377.3(DYNC2H1):c.9908T>C (p.Ile3303Thr) SNV Uncertain significance 978634 11:103114510-103114510 11:103243781-103243781

Expression for Lung Disease

Search GEO for disease gene expression data for Lung Disease.

Pathways for Lung Disease

Pathways related to Lung Disease according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 SERPINA1
2
Show member pathways
12.94 TNF SFTPD SFTPA2 IL1B IL10 IFIH1
3
Show member pathways
12.64 TNF MUC5B IL1B CXCL8 CFTR
4
Show member pathways
12.23 TNF MUC5B IL1B CXCL8 CFTR
5
Show member pathways
12.19 TNF TERT IL1B IL10 CXCL8
6 12.11 TNF IL1B IL10 CXCL8
7 12.07 SFTPD SFTPA2 SFTPA1 DYNC2H1
8
Show member pathways
12.02 TNF SFTPD SFTPA1 IL1B CXCL8 CFTR
9 12.01 TNF IL1B IL10 CXCL8
10 11.91 TNF IL1B IL10 CXCL8
11 11.83 TNF IL1B IL10 CXCL8
12 11.78 TNF IL1B CXCL8
13
Show member pathways
11.73 SFTPD SFTPC SFTPB SFTPA2 SFTPA1
14 11.71 TNF IL1B IL10
15
Show member pathways
11.68 TNF IL1B IL10
16 11.67 TNF IL1B IL10
17 11.61 TNF SFTPA2 SFTPA1 IL1B IL10 CXCL8
18
Show member pathways
11.59 TNF IL1B CXCL8
19 11.54 TNF IL1B CXCL8
20 11.48 TNF IL1B IL10 CXCL8
21 11.42 TNF IL1B IL10 CXCL8
22
Show member pathways
11.37 SFTPD SFTPA2 SFTPA1 SERPINA1
23 11.31 TNF IL1B IL10
24 11.28 TNF IL1B IL10
25 11.17 TNF IL1B IL10
26 11.08 TNF TERT SFTPC SFTPA2 SFTPA1 SERPINA1
27
Show member pathways
11.07 SFTPD SFTPC SFTPB SFTPA2 SFTPA1 ABCA3
28
Show member pathways
10.95 SFTPD SFTPC SFTPB SFTPA2 SFTPA1
29 10.94 TNF ITGA3 IL1B IL10 CXCL8